一分钟看懂
这是一项关于非小细胞肺癌的II 期研究，登记的药物或干预包括Quad Shot Radiotherapy；Tislelizumab；Carboplatin or cisplatin；Pemetrexed or Paclitaxel，当前状态为尚未开始招募。登记地点显示中国武汉有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Quad Shot Radiotherapy；Tislelizumab；Carboplatin or cisplatin；Pemetrexed or Paclitaxel · II 期
登记条件中文摘要
年龄范围：18岁至75岁
登记的基本范围为不限性别，年龄18岁至75岁；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Wuhan Union Hospital · 武汉
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- 1. Age 18-75 years, either gender.
- 2. Histologically or cytologically confirmed, untreated stage II-IIIB non-small cell lung cancer (NSCLC) (including T3-4N2 IIIB, AJCC 9th edition). Baseline staging must include PET/CT (or chest + upper abdomen contrast-enhanced CT + whole body bone scan) + brain MRI. Stage III patients will be further subdivided into IIIA and IIIB per AJCC 9th edition for separate recording, evaluation, and analysis.
- 3. Evaluated as resectable by a multidisciplinary team including thoracic surgeons.
- 4. At least one evaluable target lesion per RECIST v1.1.
- 5. ECOG Performance Status 0-1.
- 6. Adequate major organ function: Neutrophils ≥ 1.5×10\^9/L; Platelets ≥ 100×10\^9/L; Hemoglobin \> 9.0 g/dL; Serum creatinine ≤ 1.5×ULN or Creatinine Clearance (CrCl) ≥ 40 mL/min; AST/ALT ≤ 3×ULN; Total bilirubin ≤ 1.5×ULN; INR/APTT within normal range; FEV1 ≥ 1.2L or \> 40% predicted.
- 7. Signed written informed consent prior to any study-related procedures.
- 8. Investigator judges that the patient is able to comply with the study protocol, willing and able to follow visit schedules, treatment plans, laboratory tests, and other study procedures.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07845916；登记信息更新于 2026-09-29；本站同步于 2026-10-08，中国中心当前名额未经人工确认。